Clinical trial
A Phase 2 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effect of SAR443820 on Serum Neurofilament Levels in Participants With Multiple Sclerosis, Followed by an Open-label Long-term Extension Period
NCT05630547 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effect of SAR443820 on Serum Neurofilament Levels in Participants With Multiple Sclerosis, Followed by an Open-label Long-term Extension Period
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 19, 2022
- Completion date
- November 21, 2024
- Enrollment
- 174 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.